Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Industrial Estimate
Composite Estimate
500 Stocks Estimate
Gold
Crude Oil
Central Oregon Stock Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Roivant Sciences Ltd WT
(NQ:
ROIVW
)
N/A
UNCHANGED
Last Price
Updated: 3:45 PM EDT, Sep 1, 2023
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
0
Open
-
Bid (Size)
1.160 (1)
Ask (Size)
2.600 (1)
Prev. Close
2.750
Today's Range
N/A - N/A
52wk Range
N/A - N/A
Shares Outstanding
N/A
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Roivant Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2024, and Provides Business Update
May 30, 2024
From
Roivant Sciences
Via
GlobeNewswire
Roivant to Report Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2024, and Provide Business Update on Thursday, May 30, 2024
May 16, 2024
From
Roivant Sciences
Via
GlobeNewswire
Performance
More News
Read More
Roivant Announces Positive NEPTUNE Study Results for Brepocitinib in NIU, as well as Board Authorization for up to $1.5 Billion Share Repurchase Program, Including Repurchase of Entire Sumitomo Pharma Stake for $648 Million
April 02, 2024
From
Roivant Sciences
Via
GlobeNewswire
Roivant Reports Financial Results for the Third Quarter Ended December 31, 2023, and Provides Business Update
February 13, 2024
From
Roivant Sciences
Via
GlobeNewswire
Roivant to Report Financial Results for the Third Quarter Ended December 31, 2023, and Provide Business Update on Tuesday, February 13, 2024
January 30, 2024
From
Roivant Sciences
Via
GlobeNewswire
Roivant Reports Positive Initial Phase 2 Results for Batoclimab in Graves’ Disease
December 20, 2023
From
Roivant Sciences
Via
GlobeNewswire
Roche Completes Acquisition of Telavant from Roivant, Including Rights to Novel TL1A Directed Antibody (RVT-3101) for the Treatment of Inflammatory Bowel Disease
December 14, 2023
From
Roivant Sciences
Via
GlobeNewswire
Roivant Announces Positive IMVT-1402 Initial 600 mg MAD Results that Confirm Best-in-Class Potential
November 28, 2023
From
Roivant Sciences
Via
GlobeNewswire
Roivant and Priovant Announce Results from Phase 2 Study of Oral Brepocitinib in Systemic Lupus Erythematosus
November 27, 2023
From
Roivant Sciences
Via
GlobeNewswire
Roivant Reports Financial Results for the Second Quarter Ended September 30, 2023, and Provides Business Update
November 13, 2023
From
Roivant Sciences
Via
GlobeNewswire
Roivant Announces Appointment of Mayukh Sukhatme to Its Board of Directors
November 10, 2023
From
Roivant Sciences
Via
GlobeNewswire
Roivant to Report Financial Results for the Second Quarter Ended September 30, 2023, and Provide Business Update on Monday, November 13, 2023
October 30, 2023
From
Roivant Sciences
Via
GlobeNewswire
Roche Enters Into a Definitive Agreement to Acquire Telavant Including Rights to Novel TL1A Directed Antibody (RVT-3101) for the Treatment of Inflammatory Bowel Disease From Roivant
October 23, 2023
From
Roivant Sciences
Via
GlobeNewswire
Roivant Announces Positive Initial IMVT-1402 Phase 1 SAD and 300 mg Subcutaneous MAD Results
September 26, 2023
From
Roivant Sciences
Via
GlobeNewswire
Roivant Announces Completion of Redemption of its Outstanding Warrants
September 11, 2023
From
Roivant Sciences
Via
GlobeNewswire
Bill Ackman Tells Vivek Ramaswamy How To Run For President
August 24, 2023
Via
Benzinga
Presidential Hopeful Ramaswamy Predicts US Recession In 2024
August 21, 2023
Via
Benzinga
Topics
Economy
Exposures
Economy
Roivant Announces Redemption Fair Market Value in Connection with Redemption of its Outstanding Warrants
August 17, 2023
From
Roivant Sciences
Via
GlobeNewswire
Roivant Reports Financial Results for the First Quarter Ended June 30, 2023, and Provides Business Update
August 14, 2023
From
Roivant Sciences
Via
GlobeNewswire
Roivant to Report Financial Results for the Quarter Ended June 30, 2023, and Provide Business Update on Monday, August 14, 2023
August 03, 2023
From
Roivant Sciences
Via
GlobeNewswire
Roivant Announces Redemption of Outstanding Warrants
August 02, 2023
From
Roivant Sciences
Via
GlobeNewswire
Telavant, a Roivant Company, Advances Inflammatory Bowel Disease Program with First Patient Dosed in Global Phase 2 Trial of Novel Anti-TL1A Antibody RVT-3101 in Crohn’s Disease
July 27, 2023
From
Roivant Sciences
Via
GlobeNewswire
Roivant Ranks No. 25 on Fast Company’s Fifth Annual List of the 100 Best Workplaces for Innovators and is the Winner on the Science and Technology List as a Part of the Best Workplaces for Innovators Program
July 11, 2023
From
Roivant Sciences
Via
GlobeNewswire
UPDATE -- Roivant Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2023, and Provides Business Update
June 28, 2023
From
Roivant Sciences
Via
GlobeNewswire
Nasdaq, S&P 500 Futures Slip Ahead Of Powell Speech, Bank Stress Test Results: Why This Analyst Rates Stocks 'Overweight' And Says 'Buy Weakness'
June 28, 2023
Via
Benzinga
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.